893423-65-9

Usage

Core structure

1,6-Naphthyridine ring

Substitution at position 3

Phenyl group

Substitution at position 4 of the phenyl ring

1,3-Dioxolan-2-yl group

Substitution at position 5 of the naphthyridine ring

Methoxy group

Potential pharmaceutical applications

Biological activities, including anti-inflammatory, antimicrobial, and anticancer properties

Influence of methoxy and phenyl groups

May confer unique pharmacological properties

Need for further research

To fully understand the potential applications and biological and pharmacological effects of the compound

Upstream product

• 893423-62-6 tert-butyl (2-chloro-3-formylpyridin-4-yl)carbamate 
• 868280-61-9 1-[4-(1,3-dioxolan-2-yl)phenyl]-2-phenylethanone 
• 124-41-4 sodium methylate 
• 917363-82-7 5-chloro-2-(4-[1,3]dioxolan-2-yl-phenyl)-3-phenyl-[1,6]naphthyridine 
• 66739-89-7 4-(1,3-dioxolan-2-yl)benzonitrile 
• 105-07-7 4-cyanobenzaldehyde 
• 234108-73-7 (2-chloro-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 14432-12-3 4-Amino-2-chloropyridine 

Downstream Products

• 893423-67-1 4-(5-methoxy-3-phenyl-1,6-naphthyridin-2-yl)benzaldehyde 
• 1238323-83-5 2-[4-(1,3-dioxolan-2-yl)phenyl]-5-methoxy-3-phenyl-1,6-naphthyridine 1-oxide 
• 917359-62-7 9-phenyl-8-(4-{[4-(5-pyridin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)[1,2,4]triazolo[3,4-f]-1,6-naphthyridine 
• 893422-47-4 3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridin-5(6H)-one 
• 893423-88-6 4-(5-oxo-3-phenyl-5, 6-dihydro-1,6-naphthyridin-2-yl)benzaldehyde 

Relevant academic research and scientific papers

Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt

The Ser/Thr kinase Akt (Protein Kinase B/PKB) is a master switch in cellular signal transduction pathways. Its downstream signaling influences cell proliferation, cell growth, and apoptosis, rendering Akt a prominent drug target. The unique activation mechanism of Akt involves a change of the relative orientation of its N-terminal pleckstrin homology (PH) and the kinase domain and makes this kinase suitable for highly specific allosteric modulation. Here we present a unique set of crystal structures of covalent-allosteric interdomain inhibitors in complex with full-length Akt and report the structure-based design, synthesis, biological and pharmacological evaluation of a focused library of these innovative inhibitors.

INHIBITORS OF AKT ACTIVITY

The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model

A series of naphthyridine and naphthyridinone allosteric dual inhibitors of Akt1 and 2 have been developed. These compounds have been optimized to have potent dual activity against the activated kinase as well as the activation of Akt in cells. One molecu

Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors

This paper describes the improvement of cell potency in a class of allosteric Akt 1 and 2 inhibitors. Key discoveries include identifying the solvent exposed region of the molecule and appending basic amines to enhance the physiochemical properties of the

INHIBITORS OF AKT ACTIVITY

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.

INHIBITORS OF AKT ACTIVITY

The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and method

INHIBITORS OF AKT ACTIVITY

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

INHIBITORS OF AKT ACTIVITY

The present invention is directed to compounds which contain substituted napthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.